BGPT: Paper Review: Prime and target immunization protects against liver-stage malaria in mice

Explore by Goal

Quick Explanation Copied

Key take-away (evidence-grounded)

The paper claims that a prime–target regimen (prime CD8+ T cells systemically; target antigen expression to the liver) yields sterile protection against liver-stage malaria in mice and is associated with an expanded, durable pool of liver-resident memory–phenotype CD8+ T cells that are reported to be sufficient for protection.

Long Explanation

Paper review: prime + target immunization protects against liver-stage malaria in mice

Primary source:

Visual map of the logic chain (as claimed)

The diagram summarizes the paper’s reported causal/mechanistic sequence (prime→targeting→liver CD8+ T cells with residency phenotype→local clustering→CD8+ dependence→sterile protection and durability).

1) Core claimed outcomes (quantified where provided)

Sterile protection vs time after vaccination (reported headline numbers)

The paper states that mice show 100% sterile efficacy at 2 months and 70% at 6 months after the described prime–target regimen.

2) Experimental design (what they did, at the level needed to audit the claim)

Prime–target logic in mice: prime CD8+ responses via intramuscular viral vector expressing OVA (Ad.OVA-i.m.), then deliver antigen to the liver via an intravenous nanoparticle containing OVA (Np.OVA-i.v.).
Challenge models used: OVA-expressing transgenic P. berghei sporozoites (two Tg models) were used for liver-stage challenge, and vaccine efficacy was quantified using time to reach an endpoint of 1% blood parasitemia.
Readouts: survival/parasitemia endpoints; flow cytometry for OVA-specific CD8+ T cells and cytokine phenotypes; immunofluorescence imaging to visualize recruitment/clustering and effector markers; depletion and trafficking perturbation experiments to test CD8+ dependence and residency sufficiency.
Translation attempt: a small phase 1 clinical trial is described for intravenous administration of ChAd63.ME-TRAP in healthy volunteers, with safety/tolerability monitoring and ex vivo IFN-γ ELISPOT kinetics.

3) Evidence strength audit (what supports the main claim vs what remains uncertain)

3.1 Sterile protection claim

The paper reports that the Ad.OVA-i.m./Np.OVA-i.v. regimen produced sterile protection in 100% of mice across two OVA Tg P. berghei challenge models, while alternative routes/regimens failed to protect.

3.2 Mechanistic plausibility tests

CD8+ dependence: the paper reports that depleting CD8+ T cells before OVA-spz challenge ablated vaccine efficacy.

Localization/residency hypothesis: the paper reports that prime–target vaccination increases liver Ag-specific CD8+ T cells with a tissue-residency phenotype and that resident-phenotype cells are sufficient under FTY720 + splenectomy or FTY720 + CD8 depletion conditions.

3.3 Imaging-based correlation

The paper claims that clustered CD8+ T cells around infected hepatocytes express effector markers (IFN-γ and granzyme B) and that cluster formation requires cognate antigen.

3.4 Critical uncertainties / audit targets

Generalizability across Plasmodium species/strains: while the paper tests clinically relevant P. falciparum liver-stage antigens (via Tg spz and/or viral vector constructs), all efficacy is still demonstrated in mouse systems and transgenic sporozoite challenges; the paper itself notes the need for further work for evaluation in humans.
Endpoint definition and model specificity: “sterile protection” is operationalized by time-to-1% parasitemia; in liver-stage studies, differences in parasite kinetics or detection windows could alter interpretability. (This is a conceptual audit point about endpoint choice, not a claim of error.)
Human evidence scope: the phase 1 study described is primarily about safety/tolerability and immunogenicity kinetics (ELISPOT), not efficacy against infection in humans.

4) Additional visuals you can use to communicate the findings

Schematic: prime–target as a two-step system (from paper description)

The two-step prime–target structure and the stated downstream outcomes (liver resident phenotype and sterile protection) are taken directly from the paper’s reported regimen and results summary.

5) Reproducibility + statistical audit (only what the paper text provided)

The paper states that some n determination used an apriori power analysis, and that no randomization or blinding was performed; mice were excluded only when tail intravenous injections were not performed successfully.
Statistical modeling described includes linear mixed models (LMM) with experiment/tissue slice as random effects and vaccination/spz as fixed effects; survival uses Kaplan–Meier and log-rank (Mantel–Cox).

Skeptical note: the absence of blinding can increase risk of subtle bias, especially for endpoints that could be influenced by operational judgments (though the paper describes an explicit parasitemia threshold endpoint).

6) Buttons: follow-up deep dives on BGPT

Want the most rigorous cross-check? Run the Science AI agent so it can iteratively parse the paper text, extract additional figure-level claims, and reconstruct more quantitative summaries.

EVOLVE (optional)

Author reviews (BGPT buttons)

Feedback:

Updated: March 22, 2026